FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:2304-2305 November 24, 2005 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ryan, P. D. PubMed Citation

To the Editor: In her discussion of Case 24-2005 (Aug. 11 issue),¹ Dr. Ryan recommended adjuvant therapy with anastrozole (Arimidex) for a postmenopausal woman with hormone-receptor–positive breast cancer. Although the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial showed a disease-free survival advantage of 2.4 percent favoring anastrozole, there was no benefit in overall survival, and the risk of fracture with anastrozole was 7.1 percent, as compared with 4.4 percent with tamoxifen (hazard ratio, 1.61; P<0.001).²

The patient's medical problems included osteopenia, which was being treated with calcium and vitamin D. Therapy with anastrozole for five years will probably place . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.